CollPlant Biotechnologies CLGN and Stratasys Ltd. SSYS recently declared the commencement of a pre-clinical study involving 200cc commercial-sized regenerative implants fabricated on a Stratasys Origin 3D printer.
The study is anticipated to investigate the implants’ capability to induce the growth of natural breast tissue and undergo complete degradation over time. The test will scrutinize 3D printed breast implants containing 200cc in CollPlant’s rhCollagen-based bioinks volume created on a Stratasys’ Origin printer. This pre-clinical study marks a substantial leap forward in the collaborative journey of the two entities to deliver patient care via regenerative medicine instead of conventional implants.
In-depth Analysis
While CollPlant spearheads the frontier of regenerative and aesthetic medicine, pioneering innovative technologies and products based on its rhCollagen for tissue regeneration and organ production, Stratasys stands as a prominent figure in polymer 3D printing solutions. Stratasys reconfigured the Origin printer to build the regenerative implants following the partnership announcement between the two companies in April 2023. CollPlant foresees the release of initial study outcomes in the first half of 2025.
The alliance between CollPlant and Stratasys aims to develop a bioprinting resolution for CollPlant’s breast implants and optimize the implant construction process. The study’s objective is to assess the implants’ potential to prompt native breast tissue formation and eventual whole degradation.
A considerable portion of the total addressable breast implant market is poised to be conquered by CollPlant’s pioneering breast implants, engineered to regenerate an individual’s natural breast tissue without initiating an immune response. These implants have the potential to revolutionize reconstructive and cosmetic procedures.
Market Outlook
According to a report by The Brainy Insights, the global breast implant market is valued at approximately $3 billion, with breast reconstruction and augmentation procedures ranking as the second most prevalent plastic surgery performed worldwide.
Traditional breast augmentation or reconstruction procedures predominantly involve synthetic breast implantations crafted from silicone, serving as an artificial alternative to naturally regenerated tissue but carrying potential complications.
Financial Performance
Year-to-date, CLGN’s shares have experienced a 24.1% decline compared to the industry’s modest uptick of 0.2%. Simultaneously, the S&P 500 has seen a 17.7% ascension within the same timeframe.
Image Source: Zacks Investment Research
Zacks Rank & Considerable Stocks
Presently, CLGN holds a Zacks Rank #3 (Hold).
Within the broader medical sector, some more promising stocks include Universal Health Service UHS and ABM Industries ABM. Universal Health Service boasts a Zacks Rank #1 (Strong Buy), while ABM Industries carries a Zacks Rank #2 (Buy).
Universal Health Service is estimated to have a long-term growth rate of 19%. UHS has repeatedly exceeded earnings estimates over the past four quarters, averaging at 14.58%.
Year-to-date, Universal Health Service has accelerated by 41.1% in contrast to the industry’s 34.8% rise.
ABM Industries has also surpassed earnings predictions across the last four quarters, delivering an average surprise of 7.34%.
ABM’s shares have climbed by 24.1% so far this year in comparison to the industry’s 11.9% increase.